Furthermore, it is specifically expressed on primary acute myeloid leukaemia (AML) blasts and in a leukemic CD34 + CD38-stem cell compartment, which has highlighted its potential as a diagnostic and therapeutic target in AML [52,58]. This evidence concerns the gene CD34 and acute myeloid leukemia.